Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-LR1109 in advanced solid tumors and NSCLC
NCT06332755Phase 1Recruiting
- Sponsor
- LG Chem
- Start
- Jun 2024
- Primary completion
- Nov 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of LB-LR1109 in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC) and 2 more (2 arms), sponsored by LG Chem. Primary endpoints: Maximum Tolerated Dose at 1 year, Recommended Phase 2 Dose at 1 year and 3 more. Started Jun 2024; status: recruiting.
02
Drugs
LB-LR1109
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)urothelial carcinoma (UC)Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT06332755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332755.